Condition: Ovarian Cancer · Sponsor: Hospices Civils de Lyon
Poly(ADP-ribose) polymerase (PARP) inhibitors are anti-cancer treatments that induce preferential tumor cell death. Their efficacy has been demonstrated in many tumor models, primarily in advanced ovarian cancer. PARP inhibitors also exhibit a particular toxicity, damaging the hematopoietic tissue. With age, pharmacokinetic changes or a reduction in medullary cavity may increase these toxicities and may lead to dose reductions/postponements or premature discontinuation of PARP inhibitors, which may impact the efficacy of treatment. Close biological monitoring must be carried out to limit these toxicities, in most cases anemia, thrombocytopenia and neutropenia. Until now, the geriatric factors impacting the tolerance and uptake of PARP inhibitors in the elderly patient population with advanced ovarian cancer are not clearly established. It is therefore necessary to have prospective real-life data in order to support patients in a decision-making process on whether or not to continue such treatments. PARIB-OLD-PRO² will evaluate the association between various clinical, biological, and geriatric factors and the relative dose intensity (RDI) of therapy by PARP inhibitors. This is a prospective, multicenter longitudinal and non-interventional study and will involve a population of 50 patients, aged 70 years and elder, with advanced ovarian cancer who are scheduled to start a therapy with PARP inhibitors for the first time. The aim of the study is to better understand the effects…
This description comes directly from the study's public registry record.
Claire FALANDRY, Professor · 04.72.07.18.15 · claire.falandry@chu-lyon.fr
Gabriel ANTHERIEU, MD, PhD · 04.78.86.15.20 · gabriel.antherieu@chu-lyon.fr
Always discuss trial participation with your own doctor first.
| Centre Hospitalier Universitaire d'Amiens Picardie Site Sud | Amiens, France | Recruiting |
| Clinique de l'Europe | Amiens, France | Recruiting |
| Hôpital Femme-Mère-Enfant | Bron, France | Recruiting |
| Centre de lutte contre le cancer Jean Perrin | Clermont-Ferrand, France | Recruiting |
| Groupe Hospitalier Public Sud de l'Oise | Creil, France | Recruiting |
| Centre Georges François Leclerc | Dijon, France | Recruiting |
| Service Hôpital de jour / Oncologie Médicale, Hôpital de la Croix Rousse | Lyon, France | Recruiting |
| Hôpital Privé Jean Mermoz | Lyon, France | Recruiting |
| Service de Gériatrie, Hôpital Dr Frédéric Dugoujon | Lyon, France | Recruiting |
| Groupe Hospitalier Diaconesses Croix Saint Simon | Paris, France | Recruiting |
| Service Oncologie Médicale, Hôpital Lyon Sud | Pierre-Bénite, France | Recruiting |
| Clinique Mathilde | Rouen, France | Recruiting |
+ 4 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06572735